CAJ | 학술논문

目的：研究二甲双胍对糖尿病患者血糖（BG）、胰岛素（Ins）、血清纤溶酶原激活物抑制因子-1（PAI-1）及血脂水平变化的影响分析。方法选取2010年1月至2012年12月于本院就诊治疗的糖尿病患者124例，以数字法随机分为对照组（62例）和观察组（62例）。对照组患者行格列齐特缓释片治疗，观察组在对照组基础上加用二甲双胍进行治疗。观察2组患者BG、Ins、PAI-1及血脂水平变化，并对其进行对比分析。结果观察组患者治疗后BG、Ins及PAI-1值分别为（7.6±4.7）、（9.2±2.8）、（60.2±17.9）μg/L，均显著低于对照组的（10.4±3.6）、（12.5±4.7）、（69.6±22.3）μg/L，差异均有统计学意义（P<0.05）。观察组患者胆固醇、三酰甘油以及低密度脂蛋白胆固醇水平分别为（2.09±0.58）、（4.48±0.51）、（2.14±0.59） mmol/L，均显著低于对照组的（2.41±0.47）、（5.17±0.63）、（3.07±0.62） mmol/L，差异亦均有统计学意义（P<0.05）。观察组患者正常R-R间期标准差（SDNN）、相邻正常的R-R间期差值均方的平方根（RMSSD）与相邻R-R间期差值大于50 ms心搏数所占百分比（PNN50）分别为（48.4±8.5） ms、（23.7±5.4） ms、12.1%±0.6%，均显著高于对照组的（35.6±7.8） ms、（16.6±5.1）ms、8.7%±0.9%，差异均有统计学意义（P<0.05）。结论二甲双胍对糖尿病患者BG、Ins、PAI-1及血脂水平均能进行有效控制及改善，对患者而言十分有利，且其安全性好，值得临床推荐。
목적：연구이갑쌍고대당뇨병환자혈당（BG）、이도소（Ins）、혈청섬용매원격활물억제인자-1（PAI-1）급혈지수평변화적영향분석。방법선취2010년1월지2012년12월우본원취진치료적당뇨병환자124례，이수자법수궤분위대조조（62례）화관찰조（62례）。대조조환자행격렬제특완석편치료，관찰조재대조조기출상가용이갑쌍고진행치료。관찰2조환자BG、Ins、PAI-1급혈지수평변화，병대기진행대비분석。결과관찰조환자치료후BG、Ins급PAI-1치분별위（7.6±4.7）、（9.2±2.8）、（60.2±17.9）μg/L，균현저저우대조조적（10.4±3.6）、（12.5±4.7）、（69.6±22.3）μg/L，차이균유통계학의의（P<0.05）。관찰조환자담고순、삼선감유이급저밀도지단백담고순수평분별위（2.09±0.58）、（4.48±0.51）、（2.14±0.59） mmol/L，균현저저우대조조적（2.41±0.47）、（5.17±0.63）、（3.07±0.62） mmol/L，차이역균유통계학의의（P<0.05）。관찰조환자정상R-R간기표준차（SDNN）、상린정상적R-R간기차치균방적평방근（RMSSD）여상린R-R간기차치대우50 ms심박수소점백분비（PNN50）분별위（48.4±8.5） ms、（23.7±5.4） ms、12.1%±0.6%，균현저고우대조조적（35.6±7.8） ms、（16.6±5.1）ms、8.7%±0.9%，차이균유통계학의의（P<0.05）。결론이갑쌍고대당뇨병환자BG、Ins、PAI-1급혈지수평균능진행유효공제급개선，대환자이언십분유리，차기안전성호，치득림상추천。
Objective To study the effects of metformin on the blood glucose (BG), insulin (Ins), serum plasminogen activator inhibitor-1 (PAI-1) and blood lipid levels in diabetic patients. Methods Clinical data of 124 cases of diabetic patients admitted between Jan. 2010 and Dec. 2012 were retrospectively analyzed. The diabetic patients were randomly divided into the observation group (62 cases) and control group (62 cases). Patients in the observation group were treated with metformin, while the control group underwent Gliclazide sustained-release tablets treatment. Changes in BG, Ins, PAI-1 and blood lipid levels of the two groups were observed, and the contrast analysis was carried out. Results The BG, Ins and PAI-I levels of the observation group was significantly lower than that of the control group, and the differences were statistically significant (P<0.05).The cholesterol, triglyceride and low density lipoprotein cholesterol levels of patients in the observation group were significantly lower than that of the control group, and the differences were statistically significant (P<0.05). Standard deviation of NN intervals (SDNN), root mean square of successive differences (RMSSD) and percentage of adjacent NN intervals in a 24 hour recording which differ by at least 50 ms (PNN50) of the observation group were significantly higher than that of the control group, and the differences were statistically significant (P<0.05). Conclusions Metformin can effectively control the BG, Ins, PAI-1 and blood lipid levels of diabetic patient and improve the SDNN, RMSSD and PNN50, which is very favorable for the patients. Along with good safety, Metformin is suitable for clinical recommendation.